Revance Therapeutics, Inc. today announced new hire grants totaling an aggregate of 222,452 inducement restricted stock units ("RSUs") to 29 employees. The RSUs vest over four years, with 25% of the underlying shares vesting on each of the four.
Revance Therapeutics (NASDAQ:RVNC) Trading Down 3.8% theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Free Report) have earned a consensus rating of “Moderate Buy” from the eight brokerages that are covering the stock, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12 month […]
/PRNewswire/ Coherent Market Insights published a report, titled, Global Cell Penetrating Peptide Market, By Type (Protein Derived CPPs, Synthetic CPPs,.